Skip to main content Skip to main navigation menu Skip to site footer

Risk factors for disability in leprosy patients: a cross-sectional study

  • Silvani Geani ,
  • Rahmadewi ,
  • Astindari ,
  • Cita Rosita Sigit Prakoeswa ,
  • Sawitri ,
  • Evy Ervianti ,
  • Budi Utomo ,
  • Medhi Denisa ,
  • Novianti Rizky Reza ,
  • Bagus Haryo Kusumaputra ,
  • Regitta Indira Agusni ,
  • Putri Hendria Wardhani ,
  • Muhammad Yulianto Listiawan ,


Background: The disability in leprosy is caused by M. leprae invasion and infiltration into the skin and the mucous membrane that results in nerve damage and deformities, loss of sensation, paralysis, and ocular manifestation. The risk of disability can be influenced by several factors, including the type of leprosy, disease duration, the number of nerves affected, leprosy reactions, gender, age, type of treatment, socioeconomic factors, and leprosy case detection methods. This study aimed to evaluate the risk factor of disability in leprosy patients.

Methods: It was a cross-sectional retrospective analytical study to discover the correlation between risk factors with the grade of disability in leprosy patients who were treated in Dermatovenerology Outpatient Clinic Dr. Soetomo General Hospital Surabaya from 2017 to 2019.

Result: This study found a total of 275 leprosy patients with disabilities, consisting of 76 patients (27,6%) with grade-1 disability and 199 patients (72,4%) with grade 2 disability. There was a statistically significant correlation between age (p=0,025), duration of disease (p=0,001), and multidrug therapy (MDT) history (p=0,001) with the incidence of disability. Gender, bacterial index, type of leprosy, and leprosy reaction were not significantly related to disability.

Conclusion: This study showed that age, duration of disease, and the history of MDT treatment were related to the incidence of disability. The longer the disease's duration despite the patient having received MDT, the more risk of the patient having a disability.


  1. Malaviya GN. Deformity and disability prevention. In: Kumar B, Kar HK, editors. IAL textbook of leprosy. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd. 2017. p542-61.
  2. Mangala HC, Jeyaraman M, Chaudari K, Dhorde V, Likhith D. A study on prevalence of deformities in leprosy in a tertiary care hospital at Davangere. J Mycobact Dis 2019; 9: 275. DOI:10.4172/2161-1068.1000275.
  3. World Health Organization. Weekly epidemiological record. World Health Organization 2020; 95(36):417-40.
  4. Monteiro LD, Martins-Melo FR, Brito AL, Alencar CH, Heukelbach J. Physical disabilities at diagnosis of leprosy in a hyperendemic area of Brazil: trends and associated factors. Lepr Rev. 2015;86(3):240-250.
  5. Moschioni C, Antunes CM, Grossi MA, Lambertucci JR. Risk factors for physical disability at diagnosis of 19,283 new cases of leprosy. Rev Soc Bras Med Trop. 2010;43(1):19-22. doi:10.1590/s0037-86822010000100005.
  6. Raghavendra BN, Aneesh S, Yarramachu S, Anoop GDS, MuneerM. Clinical pattern of deformities and disabilities in leprosy patients in rural Bangalore – a two year study at tertiary level hospital'. Indian J Dermatol 2017; 3(3):101-9. DOI: 10.18231/2455-6769.2017.0025.
  7. Naik JD, Kamble SV, Jain SR, Mathurkar MP, Dolare JR, Patil V. A retrospective study of disability profile of live leprosy patients in a district of Maharashtra. International Journal of Medical Science and Public Health 2016; 5(1):6. DOI: 10.5455/ijmsph.2016.22102015183.
  8. Bungin C, Toruan VML, Riastiti Y. The correlation between leprosy type and grade of disability in leprosy patients in Samarinda'. Jurnal Ilmua Kesehatan 2019; 8(1):32-6. DOI:
  9. Mowla MR, Angkur DM, Hasan Z, Sultana MN, Afrin S, Akhter MS. Leprosy patients with deformities at post-elimination stage: the Bangladesh experience. Skin Health Dis 2020; 1: 1-8. DOI:10.1002/ski2.5.
  10. Reyila VP, Betsy A, Riyaz N, et al. Clinico-epidemiological Study of Disability Due to Leprosy at the Time of Diagnosis among Patients Attending a Tertiary Care Institution. Indian J Dermatol. 2019;64(2):106-111. doi:10.4103/ijd.IJD_185_17.
  11. Raposo MT, Reis MC, Caminha AVQ, et al. Grade 2 disabilities in leprosy patients from Brazil: Need for follow-up after completion of multidrug therapy. PLoS Negl Trop Dis. 2018;12(7):e0006645. Published 2018 Jul 16. doi:10.1371/journal.pntd.0006645.
  12. Mani RM, Dominic S, Vadakkayil B. Risk Factors for grade 2 disability in leprosy at the time of diagnosis. JMSCR 2019; 7(2) 193-197. doi:10.18535/jmscr/v7i2.37.
  13. Shumet T, Demissie M, Bekele Y. Prevalence of Disability and Associated Factors among Registered Leprosy Patients in All Africa Tb and Leprosy Rehabilitation and Training Centre (ALERT), Addis Ababa, Ethiopia. Ethiop J Health Sci. 2015;25(4):313-320. doi:10.4314/ejhs.v25i4.4.
  14. Sales AM, Campos DP, Hacker MA, et al. Progression of leprosy disability after discharge: is multidrug therapy enough?. Trop Med Int Health. 2013;18(9):1145-1153. doi:10.1111/tmi.12156.
  15. Jha SM, Dangol AKS, Shakya S, Jha B. Clinico- bacterial correlation of bacterial index in Hansen's disease. Journal of Pathology of Nepal. 2016; 6(12). p998-1000. DOI:10.3126/jpn.v6i12.16285.
  16. Sarkar J, Dasgupta A, Dutt D. Disability among new leprosy patients, an issue of concern: an institution based study in an endemic district for leprosy in the state of West Bengal, India. Indian J Dermatol Venereol Leprol. 2012;78(3):328-334. doi:10.4103/0378-6323.95449.
  17. Domple VK, Harnalikar MY, Wadde SK, Gadekar RD, Dhande VS. Assessment of Disability amongst Leprosy Patients: A Cross-Sectional Study. Natl J Community Med 2017; 8(8):482-486.
  18. Santos VS, de Matos AM, de Oliveira LS, et al. Clinical variables associated with disability in leprosy cases in northeast Brazil. J Infect Dev Ctries. 2015;9(3):232-238. Published 2015 Mar 15. doi:10.3855/jidc.5341.
  19. Quyum F, Hasan M, Chowdury WK, Wahab MA. Leprosy reactions: frequency and risk factors. J Clin Dermatol Ther 2016; 3: 022. doi:10.24966/CDT-8771/100022.
  20. Raffe SF, Thapa M, Khadge S, Tamang K, Hagge D, Lockwood DN. Diagnosis and treatment of leprosy reactions in integrated services--the patients' perspective in Nepal. PLoS Negl Trop Dis. 2013;7(3):e2089. doi:10.1371/journal.pntd.0002089.
  21. Lockwood DN, Saunderson PR. Nerve damage in leprosy: a continuing challenge to scientists, clinicians and service providers. Int Health. 2012;4(2):77-85. doi:10.1016/j.inhe.2011.09.006.
  22. Dos Santos AR, Silva PRS, Steinmann P, Ignotti E. Disability progression among leprosy patients released from treatment: a survival analysis. Infect Dis Poverty. 2020;9(1):53. Published 2020 May 24. doi:10.1186/s40249-020-00669-4.
  23. Kumar A, Girdhar A, Girdhar BK, Risk of developing disability in pre and post-multidrug therapy treatment among multibacillary leprosy: Agra MB cohort study. BMJ Open. 2012; 2(2):1-7. doi:10.1136/bmjopen-2011-000361.
  24. Haefner K. Walther F. Chichava OA. Ariza L. Alencar CH. de Alencar MDJF, et al. High occurrence of disabilities caused by leprosy: census from a hyperendemic area in Brazil's Savannah region. Lepr Rev. 2017; 88(4):520–32. DOI:10.47276/lr.88.4.520.

How to Cite

Geani, S., Rahmadewi, Astindari, Prakoeswa, C. R. S., Sawitri, Ervianti, E., Utomo, B., Denisa, M., Reza, N. R., Kusumaputra, B. H., Agusni, R. I., Wardhani, P. H., & Listiawan, M. Y. (2022). Risk factors for disability in leprosy patients: a cross-sectional study. Bali Medical Journal, 11(1), 197–201.




Search Panel